| 11.7056 1.756 (17.64%) | 05-12 12:16 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.2  |
1-year : | 16.58 |
| Resists | First : | 12.15 |
Second : | 14.2 |
| Pivot price | 9.92  |
|||
| Supports | First : | 9.52 |
Second : | 7.9 |
| MAs | MA(5) : | 10.12 |
MA(20) : | 10.3 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 61.2 |
D(3) : | 48.3 |
| RSI | RSI(14): 58.6 |
|||
| 52-week | High : | 16.5 | Low : | 7.9 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EIKN ] has closed below upper band by 1.4%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 10.89 - 10.93 | 10.93 - 10.98 |
| Low: | 9.78 - 9.83 | 9.83 - 9.87 |
| Close: | 9.87 - 9.94 | 9.94 - 10.02 |
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. Its products includes EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004 are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004, to address brain metastases and primary brain malignancies; EIK1005 a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006. The company was incorporated in 2019 and is based in Millbrae, California.
Mon, 11 May 2026
IPO cash lifts Eikon Therapeutics (NASDAQ: EIKN) to $596M - Stock Titan
Wed, 06 May 2026
FMR LLC holds 3.84M EIKON Therapeutics shares (NASDAQ: EIKN) - Stock Titan
Wed, 29 Apr 2026
[SCHEDULE 13G] Eikon Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Thu, 05 Feb 2026
Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld News
Thu, 05 Feb 2026
Eikon Therapeutics, Late-Stage Clinical Oncology Drug Developer, Files for Nasdaq IPO - TradingView
Wed, 04 Feb 2026
EIKN SEC Filings - Eikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 15.5 (%) |
| Held by Institutions | 30.5 (%) |
| Shares Short | 3,560 (K) |
| Shares Short P.Month | 2,170 (K) |
| EPS | -6.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -286.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.2 % |
| Return on Equity (ttm) | -125.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -189 (M) |
| Levered Free Cash Flow | -209 (M) |
| PE Ratio | -1.88 |
| PEG Ratio | 0 |
| Price to Book value | -0.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|